"Targeting Alpha2delta-1-Bound Glutamate Receptors For Treating Diseases And Disorders" in Patent Application Approval Process (USPTO 20240083951).

A patent application by Hui-lin Pan from the University of Texas System has been made available online. The invention focuses on treating chronic neuropathic pain and epilepsy by blocking the binding of a2d-1 to glutamate receptors. The invention includes isolated peptides that can achieve this, as well as pharmaceutical compositions and methods for administering these peptides. The patent application also discusses methods for treating and preventing brain injury. The invention has potential applications in treating various diseases and disorders, including neurogenic hypertension, opioid-induced analgesic tolerance and hyperalgesia, pain and epileptic seizures, and brain injury. [Extracted from the article]